Search Results - "Schoonmaker, Michele M."

Constitutive and Regulated Expression of Telomerase Reverse Transcriptase (hTERT) in Human Lymphocytes by Liu, Kebin, Schoonmaker, Michele M., Levine, Bruce L., June, Carl H., Hodes, Richard J., Weng, Nan-Ping

“…Human telomerase consists of two essential components, telomerase RNA template (hTER) and telomerase reverse transcriptase (hTERT), and functions to synthesize…”
Get full text

Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays by Emmadi, Rajyasree, Boonyaratanakornkit, Jerry B, Selvarangan, Rangaraj, Shyamala, Venkatakrishna, Zimmer, Barbara L, Williams, Laurina, Bryant, Bonita, Schutzbank, Ted, Schoonmaker, Michele M, Amos Wilson, Jean A, Hall, Leslie, Pancholi, Preeti, Bernard, Kathryn

“…The superior sensitivity and specificity associated with the use of molecular assays has greatly improved the field of infectious disease diagnostics by…”
Get full text

The interface of Medicare coverage decision-making and emerging molecular-based laboratory testing by Burken, Mitchell I, Wilson, Kathleen S, Heller, Karen, Pratt, Victoria M, Schoonmaker, Michele M, Seifter, Eric

“…: The process of obtaining Medicare coverage for clinical services (both at the national and local levels) can be complex and often leads to considerable…”
Get full text

Molecular Methods and Platforms for Infectious Diseases Testing by Emmadi, Rajyasree, Boonyaratanakornkit, Jerry B, Selvarangan, Rangaraj, Shyamala, Venkatakrishna, Zimmer, Barbara L, Williams, Laurina, Bryant, Bonita, Schutzbank, Ted, Schoonmaker, Michele M, Amos Wilson, Jean A, Hall, Leslie, Pancholi, Preeti, Bernard, Kathryn

“…The superior sensitivity and specificity associated with the use of molecular assays has greatly improved the field of infectious disease diagnostics by…”
Get full text

Factors influencing health insurers' decisions to cover new genetic technologies by Schoonmaker, M M, Bernhardt, B A, Holtzman, N A

“…To examine the relative importance of factors influencing health insurers' coverage of new genetic technologies. A national survey in which the decision makers…”
Get more information